Navigation Links
Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
Date:3/23/2009

rtnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:  Jack Lief                                   Mary Claire Duch
               President and CEO                           WeissComm Partners
                                                           Media Relations
               David Walsey                                212.301.7228
               Senior Director, Corporate Communications

               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 1682


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 GMO corn cases filed across ... are in the process of being consolidated in a ... is In Re: Syngenta AG MIR 162 Corn Litigation, ... the District of Kansas. , Management of the Syngenta ... to U.S. District Judge John W. Lungstrum.* , As ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 ... Hill was elected treasurer for the American Society ... to advancing knowledge and research in reproductive medicine. ... fills a seat on the executive board and will ... , Dr. Hill has actively supported ASRM since ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3
... NEW YORK, Nov. 4 Wall St. Network,s 3-Minute,Press ... Tracee Tolentino that,features in-depth interviews with public company executives ... show is designed to provide viewers with insight into ... growth., Shows air Monday through ...
... Nov. 4 Uroplasty, Inc. (Amex:,UPI) announced today that ... Healthcare Conference on Monday, November 10, 2008 at the ... President and Chief Executive,Officer and Medi Jiwani, Vice President ... and historical financial,performance at 4:55 p.m. Eastern Time., ...
... 4 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) today ... is scheduled to present at the Rodman & Renshaw,10th ... present,on Tuesday, November 11th, 2008 at 2:50 p.m. Eastern ... 10-12, 2008 at the,Palace Hotel in New York., ...
Cached Biology Technology:[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO 2Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
(Date:12/10/2014)... Dec. 8, 2014 You,ve been here before: you ... can,t remember your password, site key or the answer to ... first grade teacher? Today, Hoyos Labs ... app that will finally put an end to the frustration ... TM . 1U leverages a user,s smartphone to acquire ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Diego, Calif. For snakes, spiders, and other venomous creatures, ... the area on the surface of a protein that is ... constraints, say researchers from Ben Gurion University in Israel. Understanding ... unstudied toxins will do damage, and may also aid in ...
... of Toronto Scarborough (UTSC) researcher is examining how environmental ... Fatigue Syndrome. The research could lead to better insights ... Patrick O. McGowan, professor in the department of biological ... is looking at how environmentally triggered changes to gene ...
... personal tragedy of chronic alcoholism there is heartbreak in ... the heart and that mitochondria, the cellular energy factories, ... the precise mechanism. Now new experiments led by ... York State Department of Health in Albany, and Thomas ...
Cached Biology News:Molding the business end of neurotoxins 2Research examines environmental triggers altering gene function in CFS patients 2A change of heart 2
... - Fixation medium Reagent B - Permeabilisation ... fixing cells in suspension with Reagent A ... B. This procedure gives antibodies access to ... characteristics of the cells intact. Specific formulations ...
... Solution, High pH This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
... Target Retrieval Solution, High pH, Concentrated x ... intended for heat-induced target retrievel prior to ... on formalin-fixed, paraffin-embedded tissue sections mounted on ... at high pH, 9.9, is especially effective. ...
... BioLogic Maximizer kit, 110 to 220 ... monitoring and doubles flow rates and ... systems. The kit includes the Maximizer ... starter kit, tubing kit, system cable ...
Biology Products: